Targets › PRMT5
13 programs from 11 companies in 31 trials: 25 Phase 1, 6 Phase 2; Oncology, Other, Gastroenterology; next expected readout Nov 2026.
Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core…. (UniProt, O14744)
Open in Phaseline: the race on PRMT5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Navlimetostat (BMS-986504) Selective, MTA-cooperative PRMT5 inhibitor | PRMT5, MTAP | Phase 2 | Solid Tumors; Pancreatic Ductal Adenocarcinoma; Healthy Participants; Healthy Female Participants … | Nov 2026 |
| Amgen | anvumetostat PRMT5 inhibitor in MTAP-deleted tumors | PRMT5 | Phase 2 | MTAP-deleted NSCLC; Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers; Advanced MTAP-null Solid Tumors; Thoracic Tumors | Nov 2026 |
| Bristol-Myers Squibb | BMS-986504 (MRTX1719) Selective MTA-cooperative inhibitor of PRMT5 | MTAP, PRMT5 | Phase 2 | Carcinoma, Non-Small-Cell Lung; Metastatic Non-small Cell Lung Cancer With MTAP Deletion; Advanced Solid Tumors; Advanced Solid Tumors With Homozygous MTAP Deletion … | Jan 2027 |
| Tango Therapeutics | TNG456 selective PRMT5 inhibitor | PRMT5 | Phase 1 | Non Small Cell Lung Cancer | Mar 2027 |
| Servier Bio-Innovation | TNG462 PRMT5 inhibitor | PRMT5 | Phase 1 | MTAP-deleted Solid Tumors | May 2027 |
| Tango Therapeutics | TNG462 Selective PRMT5 inhibitor | PRMT5 | Phase 1 | Locally Advanced Solid Tumor; PDAC | Jun 2027 |
| Jiangsu Simcere Pharmaceutical | SCR-6920 capsule PRMT5 inhibitor | PRMT5 | Phase 1 | Solid Tumor | Oct 2027 |
| PharmaEngine | PEP08 MTA-cooperative PRMT5 inhibitor | PRMT5 | Phase 1 | Advanced Solid Tumor | Dec 2027 |
| Jubilant Therapeutics India | JBI-778 Selective PRMT5 inhibitor | PRMT5 | Phase 1 | NSCLC Patients With EGFR Activating Mutation | Mar 2028 |
| IDEAYA Biosciences | IDE892 PRMT5 inhibitor | PRMT5 | Phase 1 | NSCLC Adenocarcinoma | Apr 2028 |
| AstraZeneca | AZD3470 PRMT5 inhibitor | PRMT5 | Phase 1 | Advanced Solid Tumors That Are MTAP Deficient; Lymphoma | Dec 2028 |
| Bayer | BAY 3713372 PRMT5 inhibitor | PRMT5 | Phase 1 | MTAP-deleted Solid Tumors | Jun 2029 |
| Northwestern University | BMS-986504 PRMT5 inhibitor | PRMT5 | Phase 1 | Metastatic Biliary Tract Carcinoma | Dec 2030 |
MTAP-deleted Solid Tumors (2) Solid Tumors (1) Pancreatic Ductal Adenocarcinoma (1) Healthy Participants (1) Healthy Female Participants (1) Healthy Female Adults (1) Phase 2 Study (1) Non-Small Cell Lung Cancer (1) Advanced Cancer (1) NSCLC Adenocarcinoma (1) MTAP-deleted NSCLC (1) Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers (1)
small molecule (11), mixed (2)
Bristol-Myers Squibb (2) Tango Therapeutics (2) Bayer (1) IDEAYA Biosciences (1) Amgen (1) Jubilant Therapeutics India (1) Jiangsu Simcere Pharmaceutical (1) Northwestern University (1) AstraZeneca (1) PharmaEngine (1) Servier Bio-Innovation (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.